JPH03503120A - ヒトのガン細胞における新規なムチン様糖蛋白質表面抗原に特異的なモノクローナル抗体 - Google Patents
ヒトのガン細胞における新規なムチン様糖蛋白質表面抗原に特異的なモノクローナル抗体Info
- Publication number
- JPH03503120A JPH03503120A JP1502149A JP50214989A JPH03503120A JP H03503120 A JPH03503120 A JP H03503120A JP 1502149 A JP1502149 A JP 1502149A JP 50214989 A JP50214989 A JP 50214989A JP H03503120 A JPH03503120 A JP H03503120A
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- monoclonal antibody
- cells
- brel
- cell line
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3015—Breast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1051—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from breast, e.g. the antibody being herceptin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Pharmacology & Pharmacy (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15307288A | 1988-02-08 | 1988-02-08 | |
US153,072 | 1988-02-08 | ||
US27199488A | 1988-11-16 | 1988-11-16 | |
US271,994 | 1988-11-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH03503120A true JPH03503120A (ja) | 1991-07-18 |
Family
ID=26850130
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP1502149A Pending JPH03503120A (ja) | 1988-02-08 | 1989-01-23 | ヒトのガン細胞における新規なムチン様糖蛋白質表面抗原に特異的なモノクローナル抗体 |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP0401247A4 (es) |
JP (1) | JPH03503120A (es) |
CN (1) | CN1036793A (es) |
AU (1) | AU3049189A (es) |
ES (1) | ES2012997A6 (es) |
WO (1) | WO1989007268A1 (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU625856B2 (en) * | 1987-07-15 | 1992-07-16 | United States of America, as represented by the Secretary, U.S. Department of Commerce, The | Second generation monoclonal antibodies having binding specificity to tag-72 and human carcinomas and methods for employing the same |
US5075219A (en) * | 1989-04-05 | 1991-12-24 | John Muir Cancer & Aging Institute | Monoclonal antibody which recognizes a specific glycoprotein of a human milk-fat globule membrane mucin antigen and said mucin antigen |
GB9019553D0 (en) * | 1990-09-07 | 1990-10-24 | Unilever Plc | Specific binding agents |
FR2693233B1 (fr) * | 1992-07-02 | 1994-08-19 | Inst Francais Du Petrole | Dispositif de contrôle de l'injection pneumatique d'un mélange carbure dans un moteur à combustion interne à deux temps et utilisation associée. |
GB2273099A (en) * | 1992-11-10 | 1994-06-08 | Asta Medica Ag | Glycoprotein encoded by a human endogenous retrovirus K envelope gene |
CA2154266A1 (en) * | 1993-02-05 | 1994-08-18 | John F. Codington | Human carcinoma antigen (hca), hca antibodies, hca immunoassays, methods of imaging and therapy |
US6949244B1 (en) | 1995-12-20 | 2005-09-27 | The Board Of Trustees Of The University Of Kentucky | Murine monoclonal anti-idiotype antibody 11D10 and methods of use thereof |
US6274143B1 (en) | 1997-06-13 | 2001-08-14 | Malaya Chatterjee | Methods of delaying development of HMFG-associated tumors using anti-idiotype antibody 11D10 |
WO2012036094A1 (ja) * | 2010-09-17 | 2012-03-22 | 独立行政法人産業技術総合研究所 | 肺癌鑑別マーカー |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4522918A (en) * | 1981-12-15 | 1985-06-11 | Jeffery Schlom | Process for producing monoclonal antibodies reactive with human breast cancer |
US4753894A (en) * | 1984-02-08 | 1988-06-28 | Cetus Corporation | Monoclonal anti-human breast cancer antibodies |
-
1989
- 1989-01-23 WO PCT/US1989/000233 patent/WO1989007268A1/en not_active Application Discontinuation
- 1989-01-23 JP JP1502149A patent/JPH03503120A/ja active Pending
- 1989-01-23 EP EP19890902325 patent/EP0401247A4/en not_active Withdrawn
- 1989-01-23 AU AU30491/89A patent/AU3049189A/en not_active Abandoned
- 1989-02-07 ES ES8900430A patent/ES2012997A6/es not_active Expired - Fee Related
- 1989-02-08 CN CN89102008A patent/CN1036793A/zh active Pending
Also Published As
Publication number | Publication date |
---|---|
WO1989007268A1 (en) | 1989-08-10 |
EP0401247A1 (en) | 1990-12-12 |
CN1036793A (zh) | 1989-11-01 |
ES2012997A6 (es) | 1990-04-16 |
EP0401247A4 (en) | 1991-01-23 |
AU3049189A (en) | 1989-08-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Edwards et al. | Monoclonal antibody identification and characterization of a M r 43,000 membrane glycoprotein associated with human breast cancer | |
JP5468587B2 (ja) | Cd44の表面発現を証明する細胞の細胞毒性媒介 | |
JP2660241B2 (ja) | モノクロナール抗体 | |
JPS61502820A (ja) | ヒトガングリオシドgd↓2に向けられたモノクロ−ナル抗体 | |
CN101107267A (zh) | 对表面表达有mcsp的细胞的细胞毒性的介导 | |
JP2003508355A (ja) | 卵巣癌細胞及び骨髄腫細胞の表面糖タンパク質、それへの抗体及びその使用 | |
JPH06509641A (ja) | モノクローナル抗体oxa及びoxbを用いた卵巣癌及び子宮内膜癌の診断法 | |
US5075219A (en) | Monoclonal antibody which recognizes a specific glycoprotein of a human milk-fat globule membrane mucin antigen and said mucin antigen | |
JPH03504491A (ja) | Sf‐25結腸腺腫抗原およびその抗原を認識する抗体 | |
JPH03503120A (ja) | ヒトのガン細胞における新規なムチン様糖蛋白質表面抗原に特異的なモノクローナル抗体 | |
AU2004205435B2 (en) | Cancerous disease modifying antibodies | |
JPS62501955A (ja) | ヒト非小細胞肺癌に関するモノクローナル抗体 | |
US5077220A (en) | Monoclonal antibody specific to a novel glycoprotein antigen on human carcinoma cells | |
Burchell et al. | Antibodies to human milk fat globule molecules | |
JP2006505510A (ja) | プロバソプレシン発現癌細胞の同定および治療のための組成物およびその利用 | |
AU2003251966A2 (en) | Compositions and uses thereof for identifying and targeting provasopressin-expressing cancer cells | |
JPH05503837A (ja) | 癌関連抗原およびその抗原を認識する抗体 | |
EP0282581A1 (en) | Monoclonal paratopic molecule directed to human ganglioside gd2 | |
Hsu et al. | Biochemical and ultrastructural study of Leu M1 antigen in Reed-Sternberg cells: comparison with granulocytes and interdigitating reticulum cells | |
JPS62149700A (ja) | ヒト乳癌を指示する抗原及び該抗原に基づくアツセイ | |
Moro | The alpha-fetoprotein receptor (RECAF): characterization and potential uses for cancer diagnosis and therapy | |
Göttlinger et al. | Biochemical characterization and tissue distribution of the Cora antigen, a cell surface glycoprotein differentially expressed on malignant and benign gastrointestinal epithelia | |
Ceriani et al. | Localization of human breast tumors grafted in nude mice with a monoclonal antibody directed against a defined cell surface antigen of human mammary epithelial cells | |
Liao et al. | Human tumor and normal tissue reactivity of the anti-(breast cancer) monoclonal antibody BA-Br-3 and its similarity to the anti-(epithelial membrane antigen) monoclonal antibody E29 | |
Troyer | Biochemical and molecular characterization of the prostate-specific membrane antigen (PSMA) |